Contemporary Pediatrics week in review: FDA approvals, gut microbiomes, and back-to-school tips
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Contemporary Pediatrics' week in review: An FDA approval, gut microbiomes, and back-to-school tips | Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, August 14 - Friday, August 18, 2023) and click each link to read and watch anything you may have missed.
1.) FDA approves pozelimab-bbfg as first CHAPLE disease treatment for children, adults
Regeneron states all 10 patients achieved normalization of serum albumin and serum IgG concentrations by week 12 in a phase 2/3 trial that investigated the safety and efficacy of pozelimab-bbfg. These concentrations were maintained through 72 weeks.
Click here for the full article.
2.) FDA approves palovarotene capsules to treat fibrodysplasia ossificans progressiva
Palovarotene is now the first and only treatment for the ultra-rare bone disease fibrodysplasia ossificans progressive (FOP), which impacts approximately 400 people in the United States and 900 globally.
Click here for the full article.
3.) AAP recommends all infants receive nirsevimab to fight RSV
The recommendation from the American Academy of Pediatrics (AAP) follows the unanimous recommendation by the CDC advisory group for routine use of nirsevimab in newborns and infants younger than 8 months born into or entering their first RSV season.
Click here for the full article.
4.) Potential links between neurological, cognitive conditions and gut microbiomes of children
In this Contemporary Pediatrics video, Rob Knight, PhD, Wolfe Endowed Chair in Microbiome Science at Rady Children's Hospital-San Diego, professor of pediatrics, bioengineering, computer science and engineering, UCSD, explains correlations of the brain and gut related to neurological and cognitive conditions. He explains that discussions regarding these associations continue to occur in the field, and that there is growing interest on the subject.
Click here to watch the full interview.
5.) Chikungunya vaccine effective in adolescents after phase 3 trial
Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.
Click here for the full article.
6.) Back to school tips for parents from the American Academy of Pediatrics
These tips can be shared with your patients' parents and saved for reference throughout the school year.
